$6.47

Last traded 2025-03-10 — delisted

NASDAQ · Healthcare · Medical - Pharmaceuticals · $464.9M mcap · 17M float

Revenue

$448M -70.0% ▼

5Y CAGR: +14.3%

Gross Profit

$267M -67.0% ▼

5Y CAGR: +5.4%

Operating Income

-$547M -17.3% ▼

Net Income

-$100M -187.8% ▼

EPS (Diluted)

$-1.06 -206.0% ▼

EBITDA

-$6M -103.3% ▼

View Full Income Statement

Line Item	FY2019	FY2020	FY2021	FY2022	FY2023
Revenue	$246M	$511M	$19.4B	$1.5B	$448M
YoY Growth	+7.1%	+107.5%	+3694.4%	-92.3%	-70.0%
Cost of Revenue	$32M	$67M	$1.1B	$684M	$182M
Gross Profit	$214M	$443M	$18.3B	$808M	$267M
Gross Margin	86.8%	86.8%	94.5%	54.1%	59.5%
R&D Expenses	$24M	$49M	$155M	$442M	$345M
SG&A Expenses	$121M	$177M	$591M	$824M	$466M
Operating Expenses	$145M	$228M	$748M	$1.3B	$813M
Operating Income	$69M	$216M	$17.6B	-$466M	-$547M
Operating Margin	27.9%	42.2%	90.6%	-31.2%	-122.0%
Interest Expense	$650K	$1M	$3M	$1M	$2M
Income Before Tax	$71M	$217M	$17.6B	$25M	-$153M
Tax Expense	$6M	$31M	$3.1B	-$63M	$105M
Net Income	$45M	$110M	$8.5B	$114M	-$100M
Net Margin	18.3%	21.6%	43.7%	7.6%	-22.3%
EPS (Diluted)	$0.41	$0.97	$74.27	$1.00	$-1.06
EBITDA	$76M	$222M	$17.7B	$183M	-$6M
Shares Outstanding	110M	114M	114M	114M	100M

Line Item	FY2020 Q4	FY2021 Q1	FY2021 Q3	FY2022 Q1	FY2022 Q3	FY2023 Q1	FY2023 Q3	FY2024 Q1
Revenue	$115M	$327M	$11.0B	$8.4B	$1.2B	$280M	$140M	$308M
Cost of Revenue	$14M	$44M	$632M	$440M	$254M	$430M	$188M	$0
Gross Profit	$101M	$284M	$10.3B	$8.0B	$958M	-$150M	-$48M	$308M
Gross Margin	87.8%	86.7%	94.2%	94.8%	79.0%	-53.3%	-34.2%	100.0%
R&D Expenses	$26M	$3M	$54M	$101M	$184M	$258M	$151M	$193M
SG&A Expenses	$47M	$83M	$162M	$432M	$157M	$671M	$231M	$177M
Operating Expenses	$74M	$87M	$216M	$533M	$341M	$929M	$383M	$370M
Operating Income	$28M	$197M	$10.1B	$7.4B	$617M	-$1.1B	-$431M	-$123M
Operating Margin	24.0%	60.1%	92.3%	88.4%	50.9%	-384.5%	-306.7%	-40.0%
Interest Expense	$531K	$328K	$2M	$1M	$623K	$641K	$264K	$2M
Income Before Tax	$27M	$198M	$6.7B	$4.9B	$620M	-$570M	-$17M	-$89M
Tax Expense	$6M	$26M	$1.6B	$1.5B	$136M	-$199M	-$34M	$139M
Net Income	$11M	$109M	$5.1B	$3.4B	$485M	-$371M	$17M	-$117M
Net Margin	9.7%	33.2%	46.5%	40.0%	40.0%	-132.2%	12.0%	-38.0%
EPS (Diluted)	$0.10	$0.96	$44.80	$29.47	$4.24	$-3.73	$0.15	$-1.17
EBITDA	$28M	$200M	$10.1B	$7.5B	$695M	-$1000M	$21M	-$27M
Shares Outstanding	114M	114M	114M	114M	114M	100M	114M	100M

SVA NASDAQ